Financials in USD. Standardized financial statements.
A compact view of how Santhera Pharmaceuticals Holding AG turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $77.22M | $39.12M | $103.41M | $7.47M | -$1.59M | $15.01M | $75.38M | $31.66M | $22.94M | $19.03M |
| Revenue Growth? | +97.4% | -62.2% | +1283.8% | +568.5% | -110.6% | -80.1% | +138.1% | +38.0% | +20.5% | 0.0% |
| Cost of Revenue? | $62.75M | $15.53M | $3.23M | $3.59M | $3.77M | $10.43M | $5.45M | $4.70M | $4.10M | $3.88M |
| Gross Profit? | $14.47M | $22.96M | $100.18M | $3.88M | -$5.36M | $4.58M | $69.93M | $26.95M | $18.84M | $15.15M |
| Gross Margin? | +18.7% | +58.7% | +96.9% | +51.9% | +336.2% | +30.5% | +92.8% | +85.1% | +82.1% | +79.6% |
| Operating Expenses? | $52.31M | $56.69M | $31.34M | $55.86M | $51.53M | $57.65M | $80.37M | $78.38M | $69.29M | $48.28M |
| Operating Income? | -$37.83M | -$33.38M | $68.84M | -$51.98M | -$56.89M | -$53.08M | -$10.44M | -$51.42M | -$50.45M | -$33.13M |
| EBITDA? | -$32.14M | -$15.89M | $79.17M | -$46.78M | -$34.57M | -$53.43M | -$7.54M | -$45.62M | -$44.05M | -$29.92M |
| Income Before Tax | -$49.07M | -$41.66M | $54.82M | -$70.62M | -$54.72M | -$67.46M | -$18.39M | -$53.86M | -$51.27M | -$33.19M |
| Income Tax Expense | $185,088 | $312,000 | $38,000 | $460,000 | $809,000 | $203,000 | $579,000 | $322,000 | $257,000 | $2.22M |
| Net Income? | -$49.26M | -$41.97M | $54.78M | -$71.08M | -$55.53M | -$67.66M | -$18.97M | -$54.19M | -$51.53M | -$35.41M |
| EPS? | $-3.78 | $-3.69 | $5.18 | $-11.67 | $-16.25 | $-50.81 | $-17.26 | $-78.63 | $-82.19 | $-56.50 |
| Diluted EPS? | $-3.78 | $-3.69 | $5.01 | $-11.67 | $-16.25 | $-50.81 | $-17.26 | $-78.63 | $-82.19 | $-56.45 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality